Texas’ Arch Manning started the season as a top Heisman Trophy contender. Texas A&M’s Marcel Reed is finishing it as one. The ...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with ...
PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with ...
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard of care ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112188096/en/ The articles, information, and content displayed on this webpage ...
– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients ...
– Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 – – Closed $50 million PIPE; strong cash position of $184.2 million as of October 31 ...
Last term, Drexel University faculty members were recognized for their scholarly research and prolific academic and professional contributions. This update offers a snapshot of activity courtesy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback